Cargando…

Neurotrophic factor therapy for Parkinson's disease: past, present and future

Detalles Bibliográficos
Autores principales:	Sullivan, Aideen M., O’Keeffe, Gerard W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Highlights
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810967/ https://www.ncbi.nlm.nih.gov/pubmed/27073356 http://dx.doi.org/10.4103/1673-5374.177710

Ejemplares similares

Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2014)

The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease
por: Goulding, Susan R., et al.
Publicado: (2020)

Protocol for evaluation of neurotrophic strategies in Parkinson’s disease-related dopaminergic and sympathetic neurons in vitro
por: Hegarty, Shane V., et al.
Publicado: (2016)

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson’s disease
por: Goulding, Susan R., et al.
Publicado: (2021)

The Epigenome as a therapeutic target for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2016)

Targeting transcriptional regulators to regenerate midbrain dopaminergic axons in Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2017)

Diet quality, sleep and quality of life in Parkinson’s disease: a cross-sectional study
por: Dunk, Danielle, et al.
Publicado: (2022)

Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease
por: O'Keeffe, Gerard W., et al.
Publicado: (2017)

The class II histone deacetylases as therapeutic targets for Parkinson’s disease
por: Mazzocchi, Martina, et al.
Publicado: (2020)

Inhibition of miR-181a promotes midbrain neuronal growth through a Smad1/5-dependent mechanism: implications for Parkinson’s disease
por: Hegarty, Shane V., et al.
Publicado: (2018)

Transplantation of novel human GDF5-expressing CHO cells is neuroprotective in models of Parkinson's disease
por: Costello, Daniel J, et al.
Publicado: (2012)

STRAP and NME1 Mediate the Neurite Growth-Promoting Effects of the Neurotrophic Factor GDF5
por: Anantha, Jayanth, et al.
Publicado: (2020)

Editorial: The Role of Stem Cells, Epigenetics and MicroRNAs in Parkinson's Disease
por: Hegarty, Shane V., et al.
Publicado: (2020)

Highlight: Genomic Insights into the Past and Future of the Black Rhinoceros
por: McGrath, Casey
Publicado: (2023)

Z‐nucleic acids: Uncovering the functions from past to present
por: Tang, Qiannan
Publicado: (2022)

Histone tales: echoes from the past, prospects for the future
por: Murgatroyd, Chris, et al.
Publicado: (2010)

Expression of endogenous Mkp1 in 6-OHDA rat models of Parkinson’s disease
por: Collins, Louise M, et al.
Publicado: (2014)

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

Chronobiology of Parkinson's disease: Past, present and future
por: Asadpoordezaki, Ziba, et al.
Publicado: (2022)

Combination therapy using GDNF and cell transplant in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

NME1 Protects Against Neurotoxin-, α-Synuclein- and LRRK2-Induced Neurite Degeneration in Cell Models of Parkinson’s Disease
por: Anantha, Jayanth, et al.
Publicado: (2021)

Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates
por: Gouel, Flore, et al.
Publicado: (2019)

Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy
por: Abdelmotilib, Hisham, et al.
Publicado: (2017)

The dietary flavonoid isoliquiritigenin is a potent cytotoxin for human neuroblastoma cells
por: Alshangiti, Amnah M., et al.
Publicado: (2019)

Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy
por: Sampaio, Tuane Bazanella, et al.
Publicado: (2017)

Explorative probes and biomarkers, chronic Salmonella infections and future vaccines
por: Michán, Carmen, et al.
Publicado: (2012)

Antigen targeting to dendritic cells: Still a place in future immunotherapy?
por: Stoitzner, Patrizia, et al.
Publicado: (2022)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update
por: McFarthing, Kevin, et al.
Publicado: (2022)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
por: McFarthing, Kevin, et al.
Publicado: (2023)

The Past, Present and Future of Cardiac Resynchronization Therapy
por: O'Brien, Thomas, et al.
Publicado: (2019)

Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future
por: Tan, Yu-Yan, et al.
Publicado: (2022)

Mitochondrial Complex I deficiency: guilty in Parkinson’s disease
por: Vos, Melissa
Publicado: (2022)

HAE therapies: past present and future
por: Zuraw, Bruce L
Publicado: (2010)

Therapy for metastatic melanoma: the past, present, and future
por: Finn, Laura, et al.
Publicado: (2012)

Zeb2 is a negative regulator of midbrain dopaminergic axon growth and target innervation
por: Hegarty, Shane V., et al.
Publicado: (2017)

4-Hydroxychalcone Induces Cell Death via Oxidative Stress in MYCN-Amplified Human Neuroblastoma Cells
por: Alshangiti, Amnah M., et al.
Publicado: (2019)

Targeting α7 nicotinic acetylcholine receptors: a future potential for neuroprotection from traumatic brain injury
por: Shin, Samuel S., et al.
Publicado: (2015)

Recognition of Salmonella by Dectin-1 induces presentation of peptide antigen to type B T cells
por: Jackson, Nicola, et al.
Publicado: (2014)

The past, present, and future of disease-modifying therapies for Alzheimer’s disease
por: SUZUKI, Kazushi, et al.
Publicado: (2017)

How will previous infection or current vaccination strategies protect us from future SARS‐CoV‐2 variant infections?
por: Monteiro, Olivia
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6avvugjf7jr5fnp9phgn7kh3nh